The development of an optimal strategy for the treatment of older patients with FLT3-mutant AML is an area of active investigation, given the less robust data for the use of an FLT3 inhibitor in patients older than 60 years receiving intensive chemotherapy. Here, FLT3 is linked to acute myeloid leukemia.